



Today's Technology
Tomorrow's Therapy

Disclaimer

The material contained in this presentation must be considered as general background information on CyGenics Ltd. This presentation does not contain any earning guidance. The information presented is in summary form and where indicated figures used are un-audited. The information contained in this presentation is subject to risks and uncertainties that may cause actual results to differ materially from those indicated. This information should not be relied upon or seen as advice as to investors. Investors should obtain independent professional advice.

CyGenics Ltd

Agenda

Company
Overview &
Update

Clinical Trials
•T-cell
•Expansion

Business
Updates -
Tissue
Banking

Business
Updates -
Vaccine
Screening

Business
Updates -
Consumable
Products

Summary


*Today's Technology
Tomorrow's Therapy*

CyGenics Ltd

Company

- ASX Listed
- June 2004
- Market Cap A\$68m

- Strong cash reserves
- Growing revenues and cash flow




- USA, Asia & Australia
- 60 employees
- Highly Experienced Board & Management

- 6 IP's awarded, 25 pending
- Strong product & service pipelines
- Clinical trials

*Today's Technology
Tomorrow's Therapy*

CyGenics Ltd

Geographical Developments



*Today's Technology
 Tomorrow's Therapy*

CyGenics Ltd

Clinical Trials

Clinical
Trials
Team in
Place

T-cell
Trial -
Ahead of
Schedule

Expansion
Trial -
On track

IND Filing
In Progress

Under FDA
& TGA
Guidelines

Strong
Interest
From
Clinicians

*Today's Technology
Tomorrow's Therapy*


T-Cell Production

(Clinical Trails Plan)

Milestones so far

- Signed Key Agreements and Insurances
- Peter MacCallum Cancer Centre Training Dec04/Jan05

Current Status




*Today's Technology
Tomorrow's Therapy*

Stem Cell Expansion (Clinical Trails Plan)

Milestones so far

- Signed Key Agreements
- Murdoch Childrens Research Institute Training Dec04/Jan05

Current Status



*Today's Technology
Tomorrow's Therapy*

CyGenics Ltd

Tissue Banking (“CordLife Division”)

Rapid Sales
Growth

Good cash
flow business

Introduction
of New
Services

Strong
Birth Rates
In Asia

Rapid
Regional
Expansion

Consolidation
Opportunities

*Today's Technology
Tomorrow's Therapy*

CyGenics Ltd

Tissue Banking


("CordLife Division")

- Upgraded and expanded core laboratory in Singapore
- Establishing full service base in Hong Kong
- Expanding sales teams in Singapore, Thailand, Philippines & Indonesia
- Extended product range


CordLife Division

5% Above Budgeted
Revenue Growth as at
October 31st, 2004

FY02-04 (A\$000)



FY02-04 (A\$000)



*Today's Technology
Tomorrow's Therapy*

CyGenics Ltd

Cytomatrix & Vaccine Screening Services (“Cytomatrix Division”)

USA DOD
Contract
on Track

Strong
Interest from
Biotech &
Pharma

Focus
on New
Revenue

Full Technical
& Sales Team
in Place

Launching
Second half
FY05

Target
USA &
Europe

*Today's Technology
Tomorrow's Therapy*


CyGenics Ltd

Cytomatrix & Vaccine Screening Services

("Cytomatrix Division")

- Key account US Department of Defense
- New business head
- Commence new Vaccine Screening Services
- Good interest for service from Pharma & Biotech

Cytomatrix Division
Budgeted Revenue
Growth on Track as at
October 31st, 2004



*Today's Technology
Tomorrow's Therapy*

CyGenics Ltd

Consumable Products & Distribution (“Cell Sciences Division”)

Major
Contracts
On Track

New
Product
Extension

6 to 12 month
Evaluation to
Revenue

Growing
Distributor
Network

*Today's Technology
Tomorrow's Therapy*


CyGenics Ltd

Consumable Products & Distribution

("Cell Sciences Division")

- OEM opportunities
 - Final Negotiations on agreement with major Multinational
 - Other discussions
- Product line extension
- Growing distributor network
- Expanded technical support team

Cell Sciences Division
Budgeted Revenue
Growth on Track for Full
Financial Year, 2005



CyGenics Ltd

Summary

Strategy → Strong drive to revenue

Clinical Trials → On track → Short term result

3 Businesses → 3 Growing revenue streams

Management → Full team in each market

Low Risk → Financial, Technical & Market

*Today's Technology
Tomorrow's Therapy*